Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacologic treatment of anxiety disorders in 1989 versus 1996: Results from the Harvard/Brown anxiety disorders research program
Autore:
Salzman, C; Goldenberg, I; Bruce, SE; Keller, MB;
Indirizzi:
Harvard Univ, Sch Med, Dept Psychiat & Human Behav, Boston, MA USA HarvardUniv Boston MA USA , Dept Psychiat & Human Behav, Boston, MA USA Univ Texas, Galveston, TX 77555 USA Univ Texas Galveston TX USA 77555Univ Texas, Galveston, TX 77555 USA Brown Univ, Butler Hosp, Sch Med, Providence, RI USA Brown Univ Providence RI USA v, Butler Hosp, Sch Med, Providence, RI USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 3, volume: 62, anno: 2001,
pagine: 149 - 152
SICI:
0160-6689(200103)62:3<149:PTOADI>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
MAINTENANCE DRUG-TREATMENT; PANIC DISORDER; DEPRESSED-PATIENTS; SHORT-TERM; COMORBIDITY; ANTIDEPRESSANTS; MEDICATIONS; ALPRAZOLAM; IMIPRAMINE; EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Salzman, C Massachusetts Mental Hlth Ctr, 74 Fenwood Rd, Boston, MA 02115 USA Massachusetts Mental Hlth Ctr 74 Fenwood Rd Boston MA USA 02115
Citazione:
C. Salzman et al., "Pharmacologic treatment of anxiety disorders in 1989 versus 1996: Results from the Harvard/Brown anxiety disorders research program", J CLIN PSY, 62(3), 2001, pp. 149-152

Abstract

Objective: This article reports on the pharmacologic treatment of patientsdiagnosed with generalized anxiety disorder (GAD) enrolled in a naturalistic long-term study of anxiety disorders, with enrollment in 1989 through 1991 and follow-up in 1996. Method: 711 patients were enrolled in the study during 1989-1991, At intake, 167 patients met DSM-III-R criteria for GAD; at 1996 followup, 103 patients met these criteria. The patients were divided into 3 groups by diagnosis: GAD alone (N = 18 at intake, N = ii at follow-up), GAD comorbid with another anxiety disorder (N = 84 at intake, N = 52 at follow-up), and GAD comorbid with Research Diagnostic Criteria-defined major depressive disorder, with or without another anxiety disorder (N = 65 at intake, N = 40 at follow-up). The groups were evaluated at intake and follow-up on whether they received medication and the types of medication they received. Results: Nearly one third of patients in the 1989-1991 sample were not receiving any medication for treatment of their anxiety disorder; in 1996, 27%of patients still were receiving no medication. There was a decrease in benzodiazepine treatment and an increase in antidepressant treatment in 1996 for GAD patients who did not have comorbid depression or another anxiety disorder. Conclusion: The finding of one quarter to one third of patients with GAD receiving no medication is consistent with previous observations of undertreatment of depression. The findings on medication type suggest a shift in the type of medications being prescribed for treatment of GAD from exclusive benzodiazepine treatment to the combination of benzodiazepine and antidepressant treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 10:21:15